文献速递食管胃疾病与幽门螺杆菌消化道出血

幽门螺杆菌根除后使用SSRI的上消化道出血住院风险:倾向性评分匹配分析

Risks of hospitalization for upper gastrointestinal bleeding in users of selective serotonin reuptake inhibitors after Helicobacter pylori eradication therapy: a propensity score matching analysis.
PubMed 文献 · Aliment Pharmacol Ther · 2019-10-03

本研究基于香港全港医疗数据库,纳入接受幽门螺杆菌根除治疗后使用SSRI的患者,采用倾向性评分1:2匹配及Cox回归分析。结果显示SSRI使用者非静脉曲张性上消化道出血住院风险显著升高(HR 1.95,95%CI 1.41-2.70),且风险增加仅见于50岁以上患者。

要点

  • 幽门螺杆菌根除后使用SSRI仍与上消化道出血住院风险升高相关(HR 1.95)。
  • 风险增加仅在50岁以上患者中显著。
  • 临床对老年SSRI使用者应警惕上消化道出血风险。

核心结论

  • 幽门螺杆菌根除治疗后使用SSRI者非静脉曲张性上消化道出血住院风险仍较高,尤其50岁以上患者。

研究设计与样本

  • 采用1:2倾向性评分匹配及Cox回归模型计算风险比(HR)和95%CI。

主要发现

  • 中位随访7.74年(IQR 5.32-10.42),上消化道出血住院粗发生率为3.98/1000人年(95%CI 3.80-4.16)。
  • 1:2匹配分析中,SSRI使用者上消化道出血风险高于非使用者(HR 1.95,95%CI 1.41-2.70)。
  • 1:1匹配敏感性分析(HR 2.13,95%CI 1.50-3.02)及多变量分析1个月间隔(HR 1.81,95%CI 1.34-2.45)、3个月间隔(HR 1.61,95%CI 1.20-2.17)结果一致。
  • 按年龄分层后,SSRI相关风险增加仅在50岁以上患者中显著。

临床怎么用

  • 对幽门螺杆菌根除后使用SSRI的患者,尤其是50岁以上者,应关注上消化道出血风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) are the first-line treatment for depression but there is a concern about the risk of upper gastrointestinal bleeding (UGIB). Past studies, however, are largely confounded by the presence of Helicobacter pylori (HP). AIM: To evaluate the UGIB risk of SSRI users after treatment for HP. METHODS: This was a propensity score (PS) matched cohort study with patients who used SSRI after receiving HP eradication therapy from the Hong Kong territory-wide healthcare database. The primary outcome was hospitalisation for nonvariceal UGIB. PS matching analysis with a ratio of 1:2 plus Cox regression model was used to compute the hazards ratios (HR) and 95% CI of UGIB risk. RESULTS: In this study, 3358 SSRI users and 57 906 non-users were included. The median follow-up duration was 7.74 (interquartile range 5.32-10.42) years. The crude incidence of hospitalisation for UGIB was 3.98 (95% CI 3.80-4.16) per 1000 person-years. In the PS matching analysis of 3358 SSRI users with 6716 non-users, SSRI was associated with a higher risk of UGIB compared to non-users (HR 1.95, 95% CI 1.41-2.70). This result was consistent in sensitivity analysis with 1:1 PS matching (HR 2.13, 95% CI 1.50-3.02) and multivariable analysis with 1-month intervals (HR 1.81, 95% CI 1.34-2.45) or 3-month intervals (HR 1.61, 95% CI 1.20-2.17). After stratifying by age, the increased risk of SSRI was only significant among patients >50 years. CONCLUSION: SSRI users have a higher risk of hospitalisation for nonvariceal UGIB after treatment for HP, particularly among older patients.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Guo CG, Cheung KS, Zhang F, et al. Risks of hospitalization for upper gastrointestinal bleeding in users of selective serotonin reuptake inhibitors after Helicobacter pylori eradication therapy: a propensity score matching analysis. Aliment Pharmacol Ther. 2019. PMID: 31583734. doi:10.1111/apt.15507

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。